Literature DB >> 20927758

Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography.

Martin Brand1, Damon Bizos, Peter O'Farrell.   

Abstract

BACKGROUND: The use of prophylactic antibiotics before endoscopic retrograde cholangiopancreatography (ERCP) is recommended by all major international gastroenterological societies, especially in the presence of an obstructed biliary system. Their use is intended to decrease or eliminate the incidence of complications following the procedure, namely cholangitis, cholecystitis, septicaemia, and pancreatitis.
OBJECTIVES: To assess the benefits and harms of antibiotics before elective ERCP in patients without evidence of acute or chronic cholecystitis, or acute or chronic cholangitis, or severe acute pancreatitis. SEARCH STRATEGY: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS until March 2010. Relevant medical and surgical international conference proceedings were also searched. SELECTION CRITERIA: Only randomised clinical trials were included in the analyses, irrespective of blinding, language, or publication status. Participants were patients that underwent elective ERCP that were not on antibiotics, without evidence of acute or chronic cholecystitis, cholangitis, or severe acute pancreatitis before the procedure. We compared patients that received prophylactic antibiotics before the procedure with patients that were given placebo or no intervention before the procedure. DATA COLLECTION AND ANALYSIS: The review was conducted according to the recommendations of The Cochrane Collaboration as well as the Cochrane Hepato-Biliary Group. Review Manager 5 was used employing fixed-effect and random-effects models meta-analyses. MAIN
RESULTS: Nine randomised clinical trials (1573 patients) were included in the analyses. The majority of the trials had risks of bias. When all patients providing data for a certain outcome were included, the fixed-effect meta-analyses significantly favoured the use of prophylactic antibiotics in preventing cholangitis (relative risk (RR) 0.54, 95% CI 0.33 to 0.91), septicaemia (RR 0.35, 95% CI 0.11 to 1.11), bacteriaemia (RR 0.50, 95% CI 0.33 to 0.78), and pancreatitis (RR 0.54, 95% CI 0.29 to 1.00). In random-effects meta-analyses, only the effect on bacteriaemia remained significant. Overall mortality was not reduced (RR 1.33, 95% CI 0.32 to 5.44). If one selects patients in whom the ERCP resolved the biliary obstruction at the first procedure, there seem to be no significant benefit in using prophylactic antibiotics to prevent cholangitis (RR 0.98, 95% CI 0.35 to 2.69, only three trials). AUTHORS'
CONCLUSIONS: Prophylactic antibiotics reduce bacteriaemia and seem to prevent cholangitis and septicaemia in patients undergoing elective ERCP. In the subgroup of patients with uncomplicated ERCP, the effect of antibiotics may be less evident. Further research is required to determine whether antibiotics can be given during or after an ERCP if it becomes apparent that biliary obstruction cannot be relieved during that procedure.

Entities:  

Mesh:

Year:  2010        PMID: 20927758     DOI: 10.1002/14651858.CD007345.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  15 in total

1.  Post-endoscopic retrograde cholangiopancreatography complications: How can they be avoided?

Authors:  Juan J Vila; Everson L A Artifon; Jose Pinhata Otoch
Journal:  World J Gastrointest Endosc       Date:  2012-06-16

Review 2.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 3.  Laparoscopic cholecystectomy: consensus conference-based guidelines.

Authors:  Ferdinando Agresta; Fabio Cesare Campanile; Nereo Vettoretto; Gianfranco Silecchia; Carlo Bergamini; Pietro Maida; Pietro Lombari; Piero Narilli; Domenico Marchi; Alessandro Carrara; Maria Grazia Esposito; Stefania Fiume; Giuseppe Miranda; Simona Barlera; Marina Davoli
Journal:  Langenbecks Arch Surg       Date:  2015-04-08       Impact factor: 3.445

Review 4.  Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done?

Authors:  Goran Hauser; Marko Milosevic; Davor Stimac; Enver Zerem; Predrag Jovanović; Ivana Blazevic
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Complications of endoscopic retrograde cholangiopancreatography: how to avoid and manage them.

Authors:  Nicholas M Szary; Firas H Al-Kawas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

Review 6.  Antibiotic prophylaxis for elective hysterectomy.

Authors:  Reuben Olugbenga Ayeleke; Selma Mourad; Jane Marjoribanks; Karim A Calis; Vanessa Jordan
Journal:  Cochrane Database Syst Rev       Date:  2017-06-18

Review 7.  Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses.

Authors:  Majid A Almadi; Alan Barkun; Myriam Martel
Journal:  Am J Gastroenterol       Date:  2016-11-15       Impact factor: 10.864

8.  Antibiotic Prophylaxis Prior to Elective ERCP Does Not Alter Cholangitis Rates or Shorten Hospital Stay: Results of an Observational Prospective Study of 138 Consecutive ERCPS.

Authors:  Theodor Alexandru Voiosu; Andreea Bengus; Andrei Haidar; Mihai Rimbas; Alina Zlate; Paul Balanescu; Andrei Voiosu; Radu Voiosu; Bogdan Mateescu
Journal:  Maedica (Buchar)       Date:  2014-12

9.  Risk Factors for the Development of Stent-Associated Cholangitis Following Endoscopic Biliary Stent Placement.

Authors:  Brendan T Everett; Shelly Naud; Richard S Zubarik
Journal:  Dig Dis Sci       Date:  2019-02-20       Impact factor: 3.199

10.  Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.

Authors:  Goran Hauser; Ivana Blažević; Nermin Salkić; Goran Poropat; Vanja Giljača; Zlatko Bulić; Davor Štimac
Journal:  Surg Endosc       Date:  2016-06-17       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.